Background: There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. Methods: We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use bionic pancreas study involving 23 subjects with type 1 diabetes who wore all three devices concurrently. The primary outcome was the mean absolute relative difference (MARD) between CGM readings and point-of-care (POC) plasma-glucose (PG) values obtained approximately twice daily by the subjects. We compared PG values with CGM readings when available from all three CGMs in the 5 min preceding the PG values (n = 829 sets). Since the Libre Pro records readings every 15 min, we also did a two-way comparison between the G5 and the Eversense with a higher number of comparisons (n = 2277 sets). Results: All three CGM systems produced higher average MARDs than during in-clinic studies. However, since all three CGM systems were worn by the same individuals and used the same meter for comparator PG measurements, we could directly compare their performances. In the three-way comparison, Eversense achieved the lowest nominal MARD (14.8%) followed by Dexcom G5 (16.3%) and Libre Pro (18.0%) (Eversense vs. Libre Pro P = 0.004, other comparisons P = NS). There was a statistically significant difference (P = 0.008) in the two-way comparison of the MARDs for Eversense (15.1%) and G5 (16.9%). Conclusions: The point accuracy of the Eversense was better than two other CGMs when compared with POC PG values.
Background: There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. Methods: We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use bionic pancreas study involving 23 subjects with type 1 diabetes who wore all three devices concurrently. The primary outcome was the mean absolute relative difference (MARD) between CGM readings and point-of-care (POC) plasma-glucose (PG) values obtained approximately twice daily by the subjects. We compared PG values with CGM readings when available from all three CGMs in the 5 min preceding the PG values (n = 829 sets). Since the Libre Pro records readings every 15 min, we also did a two-way comparison between the G5 and the Eversense with a higher number of comparisons (n = 2277 sets). Results: All three CGM systems produced higher average MARDs than during in-clinic studies. However, since all three CGM systems were worn by the same individuals and used the same meter for comparator PG measurements, we could directly compare their performances. In the three-way comparison, Eversense achieved the lowest nominal MARD (14.8%) followed by Dexcom G5 (16.3%) and Libre Pro (18.0%) (Eversense vs. Libre Pro P = 0.004, other comparisons P = NS). There was a statistically significant difference (P = 0.008) in the two-way comparison of the MARDs for Eversense (15.1%) and G5 (16.9%). Conclusions: The point accuracy of the Eversense was better than two other CGMs when compared with POC PG values.
Authors: Rose A Gubitosi-Klug; Barbara H Braffett; Ionut Bebu; Mary L Johnson; Kaleigh Farrell; David Kenny; Victoria R Trapani; Lynne Meadema-Mayer; Elsayed Z Soliman; Rodica Pop-Busui; John M Lachin; Richard M Bergenstal; William V Tamborlane Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Verónica Perea; Maria José Picón; Ana Megia; Maria Goya; Ana Maria Wägner; Begoña Vega; Nuria Seguí; Maria Dolores Montañez; Irene Vinagre Journal: Diabetologia Date: 2022-05-12 Impact factor: 10.460
Authors: Molly L Tanenbaum; Laurel H Messer; Christine A Wu; Marina Basina; Bruce A Buckingham; Danielle Hessler; Shelagh A Mulvaney; David M Maahs; Korey K Hood Journal: Diabetes Res Clin Pract Date: 2021-09-14 Impact factor: 8.180
Authors: F Boscari; M Vettoretti; F Cavallin; A M L Amato; A Uliana; V Vallone; A Avogaro; A Facchinetti; D Bruttomesso Journal: J Endocrinol Invest Date: 2021-07-01 Impact factor: 4.256